|
| Status |
Public on Apr 09, 2020 |
| Title |
BV173 control |
| Sample type |
genomic |
| |
|
| Source name |
Chronic Myeloid Leukemia
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: Chronic Myeloid Leukemia
cell line: BV173
treatment: control
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Genomic DNA samples were isolated using QIAamp DNA Kit (Qiagen)
|
| Label |
Cy5 and Cy3
|
| Label protocol |
Standard Illumina Protocol
|
| |
|
| Hybridization protocol |
Bisulfite converted DNA was amplified, fragmented and hybridised to Illumina Infinium MethylationEPIC BeadChip using standard Illumina protocol.
|
| Scan protocol |
Arrays were imaged using Illumina iScan according to manufacturer's specifications (Illumina Inc.).
|
| Description |
control
|
| Data processing |
Genome Studio software (V2011.1 Methylation module 1.9.0) and MethylationEPIC_v-1-0_B4 was used. Beta values were obtained after background correction and normalization to internal controls.
[OR21forMDS_normalized_data.txt] normalized Average Beta
[non-normalized_data.txt] Unmethylated and methylated signal intensities
|
| |
|
| Submission date |
Apr 08, 2020 |
| Last update date |
Apr 09, 2020 |
| Contact name |
Shinya Kimura |
| E-mail(s) |
[email protected]
|
| Phone |
+81952342366
|
| Organization name |
Saga University
|
| Department |
Drug Discovery and Biomedical Sciences, Faculty of Medicine
|
| Street address |
5-1-1 Nabeshima
|
| City |
Saga |
| ZIP/Postal code |
849-8501 |
| Country |
Japan |
| |
|
| Platform ID |
GPL21145 |
| Series (1) |
| GSE148314 |
A new hypomethylating agent, OR-2100, resists degradation by cytidine deaminase, leading to favorable oral absorbability and anti-leukemia effects |
|
